Liminatus Pharma, Inc. - 8-K Filing
Liminatus Pharma entered into an agreement with a warrant holder to exercise existing warrants for $0.18 per share, generating approximately $1.86 million in gross proceeds before fees. In exchange, new inducement warrants were issued at the same price of $0.18 per share and will be exercisable after stockholder approval is obtained. The company plans to use net proceeds for working capital. (Items: 1.01 Entry into a Material Definitive Agreement, 3.02 Unregistered Sales of Equity Securities, 3.03 Material Modification to Rights of Security Holders, 8.01 Other Events)
Tickers: $LIMN